Multiple sclerosis and the blood-central nervous system barrier

Area of Science:

• Neuroscience
• Immunology
• Pharmacology

Background:

• The blood-central nervous system barrier (BCNSB) regulates immune cell trafficking into the CNS.
• The BCNSB is implicated in the pathophysiology of multiple sclerosis (MS), a neuroinflammatory disease.
• Leukocyte infiltration across the BCNSB triggers neuroinflammation and contributes to MS hallmarks like perivascular plaques.

Purpose of the Study:

• To elaborate on the role of the BCNSB in MS pathophysiology.
• To discuss the implications of BCNSB penetration for MS pharmacotherapy.
• To highlight drug discovery targets at the BCNSB for MS treatment.

Main Methods:

• Review of literature on BCNSB function in MS.
• Analysis of drug mechanisms targeting BCNSB interactions.
• Discussion of specific MS drugs and their BCNSB penetration capabilities.

Main Results:

• The BCNSB controls leukocyte entry into the CNS, a key factor in MS pathogenesis.
• Small molecule drugs can cross the BCNSB, offering potential for CNS-targeted MS therapy.
• Nabiximols and dalfampridine are examples of MS drugs that penetrate the BCNSB.
• Vascular cell adhesion molecule-1 (VCAM-1) and α4-β1-integrin are identified drug targets.
• Natalizumab demonstrates efficacy by blocking leukocyte adhesion via α4-β1-integrin.

Conclusions:

• The BCNSB is a critical determinant in the pathophysiology and treatment of MS.
• Targeting BCNSB interactions offers promising therapeutic strategies for MS.
• Drug development for MS should consider BCNSB permeability for effective CNS delivery.